X

Trial Profile

Phase 2 open-label sub-study evaluating the efficacy and safety of AXS-05 in patients with Major depressive disorder with suicidal ideation (COMET-SI)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Dec 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bupropion/dextromethorphan (Primary)
Indications Major depressive disorder
Focus Therapeutic Use
Acronyms COMET-SI
Sponsors Axsome Therapeutics

Most Recent Events

08 Dec 2020 Results published in the Axsome Therapeutics media release
05 Nov 2020 Status changed from active, no longer recruiting to completed, according to an Axsome Therapeutics media release.
18 Aug 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com